All News VALBIOTIS

Equities

ALVAL

FR0013254851

Real-time Euronext Paris Other stock markets 03:27:56 2024-04-25 am EDT			5-day change	1st Jan Change
3.865 ^EUR	-1.65%		-0.51%	-22.70%

Apr. 03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF
2023	Valbiotis: capital increase successfully completed	CF

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valbiotis: launch of Valbiotis PRO Cholesterol in May	Apr. 03	CF
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May	Apr. 03	EQ
Valbiotis presents its 2024 financial communication calendar	Jan. 29	EQ
Valbiotis sets out its commercial and clinical roadmap for 2024	Jan. 16	EQ
Valbiotis: capital increase successfully completed	Dec. 22	CF
Valbiotis announces the success of its €15 M capital increase	Dec. 22	EQ
Valbiotis: 15 ME capital increase	Dec. 12	CF
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA	Dec. 12	MT
Valbiotis announces the launch of a capital increase	Dec. 11	EQ
Valbiotis announces the availability of an amendment to the Universal Registration Document	Dec. 11	EQ
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status	Dec. 11	EQ
VALBIOTIS SA:	Dec. 04	EQ
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes	Nov. 07	EQ
VALBIOTIS : Rapport financier semestriel 2023	23-10-15	PU
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes	23-10-02	EQ
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap	23-09-28	EQ
Valbiotis presents the full results of the Phase II/III REVERSE-IT study, impressive efficacy of TOTUM 63 against prediabetes and the early stages of type 2 Diabetes, a first for a non-drug active substance	23-09-12	AQ
Valbiotis: share price rises on success of clinical study	23-09-12	CF
Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance	23-09-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News VALBIOTIS

Equities

ALVAL

FR0013254851

All News

Filters